Association between metformin prescription and growth rates of abdominal aortic aneurysms

作者：Golledge, J.^*; Moxon, J.; Pinchbeck, J.; Anderson, G.; Rowbotham, S.; Jenkins, J.; Bourke, M.; Bourke, B.; Dear, A.; Buckenham, T.; Jones, R.; Norman, P. E.

来源：British Journal of Surgery, 2017, 104(11): 1486-1493.

DOI：10.1002/bjs.10587

• RUPTURE
• CELLS
• SURVEILLANCE
• PREVALENCE
• EXPANSION
• DISEASE
• VOLUME
• RISK

BackgroundIt has been suggested that diabetes medications, such as metformin, may have effects that inhibit abdominal aortic aneurysm (AAA) growth. The aim of this study was to examine the association of diabetes treatments with AAA growth in three patient cohorts.
MethodsAAA growth was studied using ultrasound surveillance in cohort 1, repeated CT in cohort 2 and more detailed repeat CT in cohort 3. Growth was estimated by the mean annual increase in maximum AAA diameter.
ResultsA total of 1697 patients with an AAA were studied, of whom 118, 39 and 16 patients were prescribed metformin for the treatment of diabetes in cohorts 1, 2 and 3 respectively. Prescription of metformin was associated with a reduced likelihood of median or greater AAA growth in all three cohorts (cohort 1: adjusted odds ratio (OR) 059, 95 per cent c.i. 039 to 087, P = 0008; cohort 2: adjusted OR 038, 018 to 080, P = 0011; cohort 3: adjusted OR 013, 003 to 061, P = 0010). No other diabetes treatment was significantly associated with AAA growth in any cohort.
ConclusionThese findings suggest a potential role for metformin in limiting AAA growth.
Worth an RCT

• 出版日期2017-10